54例新型抗肿瘤药物不良反应报告分析  

Analysis of 54 cases of adverse drug reactions induced by new antitumor drugs

作　　者：程军[1] 韩一萱[1] 汪龙[1] 朱玲娜[1] CHENG Jun;HAN Yi-xuan;WANG Long;ZHU Ling-na(Department of Pharmacy,The Third People's Hospital of Bengbu,Bengbu 233000,China)

机构地区：[1]蚌埠市第三人民医院药学部,蚌埠233000

出　　处：《中国新药杂志》2021年第3期280-284,共5页Chinese Journal of New Drugs

摘　　要：目的:了解新型抗肿瘤药物不良反应的发生规律及特点,为临床合理用药提供参考。方法:收集2015年1月—2019年12月我院上报蚌埠市药品不良反应中心关于使用的新型抗肿瘤药物引起的54例不良反应进行分析。结果:54例新型抗肿瘤药物不良反应中,男性多于女性,以≥51岁的老年人群为主(45例,83.3%)。涉及新型抗肿瘤药物15种,发生不良反应的新型抗肿瘤药物以利妥昔单抗最多。新型抗肿瘤药物不良反应累及系统-器官的主要是皮肤及附件损害(19.8%)、消化系统损害(17.3%)。结论:新型抗肿瘤药物临床应用广泛,应重视其不良反应,保障患者安全有效使用新型抗肿瘤药物。Objective: To assess the general patterns and characteristics of adverse drug reactions (ADRs)induced by new antitumor drugs and provide reference for clinical medicination. Methods: A total of 54 cases of ADR induced by new antitumor drugs were collected from January 2015 to December 2019 in Bengbu Adverse Drug Reaction Center,and analyzed statistically. Results: In the 54 ADR cases,male patients were more than females.The majority of the patients with ADR were over the age of 51 (n = 45,83. 3%). The ADR cases were related to 15 kinds of new antitumor drugs,of which the drug rituximab was the one that caused the most ADR. The main consequences of these ADR cases involved following damages: skin and its accessories damage (19. 8%) and digestive system damage (17. 3%). Conclusion: New antitumor drugs have been widely used in clinical. Clinicians and pharmacists should reinforce the monitoring on its using to ensure the safe and effective clinical application of new antitumor drugs.

关 键 词：新型抗肿瘤药物 药品不良反应 报告 

分 类 号：R969.3[医药卫生—药理学]